SCHEMBL18044895

SCHEMBL18044895

CCc1cc(C(=O)Nc2sc(S(=O)(=O)C3CNCCO3)cc2C(N)=O)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ USP2 O75604 2/20 0.36
▸ ALOX15 P16050 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ CFTR P13569 4/20 0.36
▸ CHEK1 O14757 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HCAR2 Q8TDS4 1/20 0.33
▸ TAAR1 Q96RJ0 2/20 0.33
▸ SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044885 0.91 CFTR (0.43) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044879 0.88 AURKA (0.38) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044874 0.85 CFTR (0.44) ALOX15CFTRCHEK1
SCHEMBL18044877 0.82 CFTR (0.38) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044875 0.81 SLC6A3 (0.51) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044865 0.81 IKBKB (0.41) ALDH1A1MAPTCFTRCHEK1MEN1
SCHEMBL18044866 0.81 CFTR (0.36) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044863 0.81 CFTR (0.36) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044883 0.79 CFTR (0.40) ALDH1A1MAPTUSP2ALOX15HSD17B10
SCHEMBL18044862 0.79 CFTR (0.39) CFTRCHEK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867806-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2018-01-16 — — US disclosed
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC3, ABCC5 ALDH1A1 1522/4885MAPT 4876/4885USP2 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback